Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer.

Goodwin JS, Zhou J, Kuo YF, Baillargeon J. Risk of Jaw Osteonecrosis After Intravenous Bisphosphonates in Cancer Patients and Patients Without Cancer. Mayo Clin Proc. 2017 Jan; 92(1):106-113.

View in: PubMed

subject areas

Administration, Oral
Aged
Aged, 80 and over
Bone Density Conservation Agents
Diphosphonates
Dose-Response Relationship, Drug
Female
Humans
Male
Medicare
Neoplasms
Osteoporosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
United States

authors with profiles

J Shawn Goodwin

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support